Delivery Order SPE2DB20D2104-SPE2DB23FR96G
- Not listed
- This federal contract award is for the delivery of the pharmaceutical product Xulane, a birth control patch, to the Defense Logistics Agency (DLA). The $13,413.24 firm fixed-price delivery order was issued to the prime contractor, Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which is registered in the System for Award Management (SAM.gov). This contract is not...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xulane 150-35 mcg/day patch. The $8,922.64 firm fixed-price contract has a completion date of May 25, 2022. Amerisourcebergen Drug Corp is a subsidiary of the parent company Cencora, Inc., which holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical to provide a comprehensive range of...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the pharmaceutical distribution company Cencora, Inc. The $1,612.53 firm fixed-price delivery order is for the supply of XULANE 150-35 MCG/DAY PATCH 3S, a contraceptive patch, with a period of performance through January 4, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the parent company Cencora, Inc. The $1,355.75 firm fixed-price delivery order is for the pharmaceutical product Xulane 150-35 mcg/day patch, a contraceptive medication. The contract has an ultimate completion date of May 22, 2023 and is not designated with any set-aside requirements, indicating open competition. Amerisourcebergen Drug Corp holds a significant $999,999,999...
- This federal contract award, valued at $3,162.43, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Xulane 150-35 mcg/day patch, a contraceptive product, and is classified as a Firm Fixed Price Delivery Order. The contract has an ultimate completion date of April 11, 2025 and is not set aside for any specific business category. Amerisourcebergen Drug Corp holds...
- This federal contract award was made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $7,401.85, is a delivery order for the supply of Xulane 150-35 mcg/day patch, a hormonal contraceptive product. The contract is a firm fixed-price arrangement with an ultimate completion date of April 29, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Xulane 150-35 mcg/day Patch 3s, a prescription contraceptive patch. The contract has a ceiling value of $2,033.04 and a completion date of March 2, 2023. This is a firm fixed-price delivery order contract with no set-aside designation, indicating open...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract worth $1,125.45 to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is for the supply of Xulane 150-35 mcg/day contraceptive patches. This delivery order is part of a larger indefinite delivery contract (IDC) worth up to $999,999,999.00 between DLA and Amerisourcebergen Drug Corp, which serves as the primary...
- This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., was issued by the Defense Logistics Agency (DLA) for the delivery of Xulane 150-35 mcg/day patch. The $6,020.32 firm fixed-price delivery order has a completion date of May 6, 2024. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp is a major pharmaceutical distributor that has been awarded numerous federal contracts, including a $999,999,999 Indefinite Delivery Contract (IDC) with...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Xulane contraceptive patches. The $17,337.58 firm fixed-price contract, which has an ultimate completion date of May 24, 2024, is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FR96GDelivery Order
This federal contract award, with a ceiling value of $1,127.40, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract covers the delivery of Xulane 150-35 mcg/day contraceptive patches. Amerisourcebergen Drug Corp is a subsidiary of Cencora, Inc., a for-profit organization that is registered in the System for Award Management (SAM.gov) through June 2025. The contract has no set-aside designation, indicating open competition. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026, which serves as the primary vehicle for the company to provide a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The company also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.1k | 1/26/23 |